peds.hyperbilirubinemia-neonatal.v1PRODUCTION

peds.hyperbilirubinemia-neonatal.v1

Neonatal hyperbilirubinemia — kernicterus prevention (AAP 2022 thresholds)

pediatricsacutesubacuteneonatal

Hard-required inputs

0 / 14

Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame the neonate by gestational age (≥ 38 wk vs 35 ≤ x < 38 wk vs < 35 wk explicit-AAP-exclusion), postnatal hours of age (drives hour-specific TSB curve placement), and birth weight. Jaundice visible < 24 h of life is always pathologic and never physiologic per AAP 2022.

Inputs

Actions

Advance rule

Set

Advance when

GA cohort + hours-of-age + birth-weight captured; < 35 wk → defer to hematology/case-by-case framework not AAP 2022 curves

Patient inputs (16)

maternal_blood_type_and_rh*lab • CONTEXT

Maternal Rh-neg OR O with infant A/B sets up isoimmune workup (DAT, retic, peripheral smear); guides IVIG decision

feeding_method_and_intake_assessment*history • CONTEXT

not present

Exclusive BF + > 10% weight loss + low urine output → enteral supplementation + lactation consult + serum sodium check (hypernatremic dehydration)

family_history_g6pd_or_hemolysis_or_sibling_phototherapy*history • CONTEXT

not present

Sibling-phototherapy history + family G6PD / hereditary hemolysis raise pretest probability + influence follow-up timing

cephalohematoma_or_bruising*symptom • CONTEXT

Heme load from extravascular blood delayed → peak TSB may be at 5-7 d (not 3-5 d); informs follow-up timing

gestational_age_weeks*demographic • FRAME

GA ≥ 38 wk vs 35 ≤ x < 38 wk drives separate AAP 2022 Figure 2 + 3 threshold curves; < 35 wk is explicitly excluded by AAP 2022 (case-by-case + hematology)

birth_weight_grams*demographic • FRAME

Birth weight for dosing (IVIG g/kg, exchange volume 160 mL/kg); also a risk-stratification anchor

postnatal_hours_of_age*demographic • FRAME

Hours-of-age drives placement on AAP 2022 phototherapy + exchange curves (hour-specific TSB framework; Bhutani 1999 nomogram); jaundice < 24 h is always pathologic

total_serum_bilirubin*lab • INITIAL_WORKUP

TSB drives phototherapy + exchange threshold decisions per AAP 2022; preferred over TcB if TcB > 12 mg/dL or post-phototherapy

direct_conjugated_bilirubin*lab • INITIAL_WORKUP

Direct bili ≥ 1 mg/dL (if total ≤ 5) OR ≥ 20% of total → conjugated component is pathologic + out of AAP 2022 framework; routes to peds-GI/hepatology (biliary atresia rule-out by 4 wk; Kasai outcomes time-sensitive)

infant_blood_type_and_dat_coombs*lab • INITIAL_WORKUP

DAT (direct antiglobulin test) positive + maternal-infant ABO/Rh mismatch + rising bilirubin = isoimmune hemolytic disease → IVIG 0.5-1 g/kg + close monitoring; exchange if continued rise

g6pd_screen*lab • INITIAL_WORKUP

AAP 2022 universal G6PD testing in ALL infants requiring phototherapy regardless of family history (broader than 2004); positive G6PD elevates risk and influences trigger-avoidance counseling

cbc_with_retic_and_smear*lab • INITIAL_WORKUP

Hemolysis workup: low Hgb + elevated retic + RBC fragmentation on smear supports hemolytic etiology (isoimmune, G6PD, hereditary spherocytosis)

neurologic_signs_lethargy_tone_cry*symptom • RED_FLAGS

ABE neurologic signs (lethargy + hypotonia/hypertonia + opisthotonus + retrocollis + high-pitched cry) mandate emergent exchange even before TSB confirmation

systemic_illness_sepsis_features*symptom • RED_FLAGS

Lethargy + temperature instability + poor feeding + delayed-onset jaundice OR conjugated component → consider sepsis (route to id.neonatal-sepsis.early-late.v1) per AAP 2022 risk factor list

transcutaneous_bilirubinlab • ENTRY

TcB validated as screening tool per AAP 2022; mandates TSB confirmation if > 12 mg/dL or post-phototherapy

albuminlab • INITIAL_WORKUP

Hypoalbuminemia < 3.0 g/dL is a Kemper AAP 2022 risk factor (free bilirubin crosses BBB more readily); informs threshold-curve selection

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement

informationallife_threateningacute_bilirubin_encephalopathy_signs
ABE neurologic features — lethargy + poor feeding + hypotonia OR hypertonia + opisthotonus + retrocollis + high-pitched cry — life-threatening pre-kernicterus phase; emergent exchange transfusion + ICU + neuro consult; reversible if caught early (Watchko & Tiribelli NEJM 2013; Kemper AAP 2022)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningbilirubin_above_exchange_threshold_at_aap_2022
TSB at or above AAP 2022 Figure 3 exchange-transfusion curve for gestational age + hours of age + risk factors — life-threatening; emergent exchange + intensive phototherapy + hematology + IVIG if isoimmune (Kemper AAP 2022 PMID 35927462)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalsevereisoimmune_hemolytic_disease_rh_or_abo
Isoimmune hemolytic disease — DAT (Coombs) positive + maternal-infant ABO or Rh mismatch + rising bilirubin → IVIG 0.5-1 g/kg + intensive phototherapy + close monitoring; exchange if continued rise (Kemper AAP 2022; Cochrane IVIG reviews)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalsevereg6pd_deficiency_at_phototherapy
G6PD deficiency identified in infant requiring phototherapy — AAP 2022 universal G6PD testing recommendation (broader than 2004 history-based criterion); treat aggressively; consider IVIG if also isoimmune; avoid offending meds (sulfa, nitrofurantoin, primaquine, methylene blue) and counsel on fava-bean avoidance (Kemper AAP 2022)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverepreterm_lower_threshold_curves
Preterm < 35 wk GA — AAP 2022 explicitly excludes < 35 wk from its phototherapy + exchange curves; lower thresholds appropriate but case-by-case + hematology consult; separate AAP statement for preterm pending (Kemper AAP 2022 scope caveat)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalsevereinadequate_feeding_dehydration_with_hyperbili
Exclusive BF + > 10% weight loss + low urine output + jaundice triad — supplement (expressed breast milk or formula per lactation plan); lactation consult; reassess weight + urine output + serum sodium (hypernatremic dehydration risk) (Kemper AAP 2022 BF assessment)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverehome_phototherapy_failure_or_progression
TSB rising despite home phototherapy OR not falling at expected rate → admission for intensive phototherapy + reassessment; rule out hemolysis (DAT, G6PD, retic) + sepsis features (Kemper AAP 2022; Maisels CMAJ 2015)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverelate_preterm_higher_risk_for_progression
Late preterm 35-36 wk GA + exclusive breastfeeding + early discharge → higher kernicterus risk; closer follow-up — 24 h reassessment + Bhutani-zone tracking + lactation consult (Bhutani 1999 percentile risk + Kemper AAP 2022 late-preterm caveat)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalmilddischarge_pre_aap_safety_check_at_24_48h
Universal pre-discharge bilirubin screening — TSB or TcB at discharge OR by 24-48 h of life with Bhutani 1999 nomogram percentile zone (low / low-intermediate / high-intermediate / high) + risk-stratified follow-up timing (AAP 2022 strong recommendation; Bhutani 1999 PMID 9917432)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalmildparental_education_kernicterus_prevention
Universal parental counseling on jaundice warning signs (cephalo-caudal progression face → torso → extremities; lethargy + poor feeding + arching) + when to seek evaluation; especially for high-risk infants (Kemper AAP 2022 strong recommendation)
Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENToptionalDrives dose adjustment

Loading…

Recommended regimen

Neonatal hyperbilirubinemia — by AAP 2022 threshold zone (Kemper PMID 35927462)

axis: hyperbilirubinemia_by_aap_2022_threshold_zone

Selected axis "Neonatal hyperbilirubinemia — by AAP 2022 threshold zone (Kemper PMID 35927462)" by default fallback (first axis)

phototherapy_standard_or_intensive
first line
phototherapy_device
Standard: 8-10 µW/cm²/nm at 460-490 nm blue light; Intensive: ≥ 30 µW/cm²/nm with multiple light banks + minimal swaddling • transdermal_phototherapy • continuous with breaks for feeding only if standard; uninterrupted if intensive near exchange
triggers: tsb_above_phototherapy_threshold_aap_2022
Mechanism: 460-490 nm blue light isomerizes bilirubin to water-soluble lumirubin excreted in bile/urine; intensive reduces TSB ~ 0.5-1 mg/dL per hour (Kemper AAP 2022)
ivig
add on
immunoglobulin
0.5-1 g/kg IV over 2-4 h; may repeat in 12 h if no response • IV • one dose, repeat at 12 h if no response
triggers: isoimmune_hemolytic_disease_with_rising_bilirubin_despite_intensive_phototherapy, tsb_within_2_to_3_mg_dl_of_exchange_threshold_in_isoimmune
Saturates Fc receptors on reticuloendothelial macrophages, reducing antibody-coated RBC destruction in isoimmune hemolytic disease (Rh, ABO); reduces need for exchange transfusion per Cochrane + AAP 2022
rxcui 1426680
exchange_transfusion_double_volume
first line
procedural_blood_exchange
Double-volume exchange = 160 mL/kg via central / umbilical venous catheter (UVC); typically using reconstituted whole blood (RBC + FFP), irradiated, CMV-seronegative, < 7 d old • central_venous_catheter_UVC_or_central • one procedure; repeat if TSB rebounds back above exchange threshold
triggers: tsb_above_exchange_threshold_aap_2022, acute_bilirubin_encephalopathy_neurologic_signs
Removes ~ 85% of circulating bilirubin + ~ 25-50% of extravascular bilirubin; corrects anemia in isoimmune; emergent procedure for ABE or TSB above exchange curve (Kemper AAP 2022)
enteral_feeding_supplementation
add on
nutritional_supplementation
Supplemental expressed breast milk OR formula per lactation consult; reassess weight + urine output + serum sodium • enteral_PO_or_NG • after every 2-3 h BF attempt or per lactation plan
triggers: exclusive_bf_with_gt_10pct_weight_loss_and_low_urine_output_and_jaundice
Reduces enterohepatic recirculation of bilirubin; corrects dehydration; AAP 2022 BF + intake assessment recommendation
iv_fluids_maintenance_or_resuscitation
add on
crystalloid
D10W or D10NS at maintenance (4-2-1 rule by weight) if dehydrated or NPO; resuscitation 10-20 mL/kg NS slowly if hypotensive (neonatal-specific slower bolus rate) • IV • continuous
triggers: dehydration_with_hypernatremia_or_hypotension_neonate
Correct dehydration; phototherapy increases insensible water loss 10-20%; sepsis-associated shock requires fluid resuscitation per AAP/PALS neonatal-adapted

outpatient playbook — drug actions (4)

1. home phototherapy if eligible
Standard phototherapy device, home use; reassess TSB at 24 h • transdermal_phototherapy_home • continuous with breaks for feeding only; 24 h reassessment
trigger: TSB at or above phototherapy curve, low risk, reliable caregiver, outpatient peds access
Maisels CMAJ 2015 — home phototherapy effective in selected low-risk cases; reduces hospitalization burden
2. rebound TSB check at 12-24 h post-discontinuation if elevated risk
TSB measurement • lab • one-time recheck
trigger: Phototherapy discontinued in elevated-risk infant
Rebound TSB at 12-24 h is common (Maisels CMAJ 2015)
3. iron supplementation per AAP preterm guidelines
2-4 mg/kg/day elemental iron PO from age 1 mo (preterm) or 4 mo (term) • PO • daily
trigger: Standard preterm or post-hemolysis anemia supplementation
AAP iron supplementation guidelines; especially post-isoimmune hemolytic disease cohorts
4. vitamin D + multivitamin per AAP
400 IU/day vitamin D • PO • daily
trigger: Standard newborn supplementation
AAP newborn nutrition guidelines

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Visible jaundice in neonate ≥ 35 wk GA — screening TSB or TcB indicated (Kemper AAP 2022 PMID 35927462); Universal pre-discharge bilirubin screening — TSB or TcB at discharge OR by 24-48 h of life (Kemper AAP 2022 strong recommendation); TSB at or above AAP 2022 Figure 2 phototherapy curve for GA + hours-age + risk factors (Kemper AAP 2022).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Neonatal hyperbilirubinemia — kernicterus prevention (AAP 2022 thresholds)** (peds.hyperbilirubinemia-neonatal.v1).
Phenotype framing: Physiologic jaundice (peak day 3-5; transitional UDPGT immaturity). Breastfeeding jaundice (inadequate intake → enterohepatic recirculation increased). Breast-milk jaundice (later onset day 7-14; β-glucuronidase in milk). Isoimmune hemolytic (Rh, ABO, minor antigens — Kell, Duffy, c). G6PD deficiency. Sepsis. Hereditary spherocytosis / RBC enzymopathies. Cephalohematoma / extensive bruising. Hypothyroidism. Crigler-Najjar (rare, severe). Gilbert syndrome (typically not neonatal-presenting). Conjugated: biliary atresia (Kasai by 4 wk!); neonatal hepatitis; TPN-associated cholestasis; alpha-1-antitrypsin deficiency; sepsis-associated cholestasis; HSV / TORCH hepatitis.
Scope: Frame the neonate by gestational age (≥ 38 wk vs 35 ≤ x < 38 wk vs < 35 wk explicit-AAP-exclusion), postnatal hours of age (drives hour-specific TSB curve placement), and birth weight. Jaundice visible < 24 h of life is always pathologic and never physiologic per AAP 2022.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Neonatal hyperbilirubinemia — by AAP 2022 threshold zone (Kemper PMID 35927462)**.
1. phototherapy_standard_or_intensive Standard: 8-10 µW/cm²/nm at 460-490 nm blue light; Intensive: ≥ 30 µW/cm²/nm with multiple light banks + minimal swaddling transdermal_phototherapy continuous with breaks for feeding only if standard; uninterrupted if intensive near exchange (phototherapy_device, first line) — Mechanism: 460-490 nm blue light isomerizes bilirubin to water-soluble lumirubin excreted in bile/urine; intensive reduces TSB ~ 0.5-1 mg/dL per hour (Kemper AAP 2022)
2. ivig 0.5-1 g/kg IV over 2-4 h; may repeat in 12 h if no response IV one dose, repeat at 12 h if no response (immunoglobulin, add on) — Saturates Fc receptors on reticuloendothelial macrophages, reducing antibody-coated RBC destruction in isoimmune hemolytic disease (Rh, ABO); reduces need for exchange transfusion per Cochrane + AAP 2022
3. exchange_transfusion_double_volume Double-volume exchange = 160 mL/kg via central / umbilical venous catheter (UVC); typically using reconstituted whole blood (RBC + FFP), irradiated, CMV-seronegative, < 7 d old central_venous_catheter_UVC_or_central one procedure; repeat if TSB rebounds back above exchange threshold (procedural_blood_exchange, first line) — Removes ~ 85% of circulating bilirubin + ~ 25-50% of extravascular bilirubin; corrects anemia in isoimmune; emergent procedure for ABE or TSB above exchange curve (Kemper AAP 2022)
4. enteral_feeding_supplementation Supplemental expressed breast milk OR formula per lactation consult; reassess weight + urine output + serum sodium enteral_PO_or_NG after every 2-3 h BF attempt or per lactation plan (nutritional_supplementation, add on) — Reduces enterohepatic recirculation of bilirubin; corrects dehydration; AAP 2022 BF + intake assessment recommendation
5. iv_fluids_maintenance_or_resuscitation D10W or D10NS at maintenance (4-2-1 rule by weight) if dehydrated or NPO; resuscitation 10-20 mL/kg NS slowly if hypotensive (neonatal-specific slower bolus rate) IV continuous (crystalloid, add on) — Correct dehydration; phototherapy increases insensible water loss 10-20%; sepsis-associated shock requires fluid resuscitation per AAP/PALS neonatal-adapted

Setting playbook (outpatient) — Newborn nursery pre-discharge screening + outpatient peds follow-up post-discharge. Universal pre-discharge bilirubin screening with Bhutani-percentile risk stratification + follow-up timing. Home phototherapy in selected low-risk cases. Long-term G6PD-trigger counseling + neurodevelopmental screening for at-risk infants.
6. home phototherapy if eligible Standard phototherapy device, home use; reassess TSB at 24 h transdermal_phototherapy_home continuous with breaks for feeding only; 24 h reassessment — TSB at or above phototherapy curve, low risk, reliable caregiver, outpatient peds access (Maisels CMAJ 2015 — home phototherapy effective in selected low-risk cases; reduces hospitalization burden)
7. rebound TSB check at 12-24 h post-discontinuation if elevated risk TSB measurement lab one-time recheck — Phototherapy discontinued in elevated-risk infant (Rebound TSB at 12-24 h is common (Maisels CMAJ 2015))
8. iron supplementation per AAP preterm guidelines 2-4 mg/kg/day elemental iron PO from age 1 mo (preterm) or 4 mo (term) PO daily — Standard preterm or post-hemolysis anemia supplementation (AAP iron supplementation guidelines; especially post-isoimmune hemolytic disease cohorts)
9. vitamin D + multivitamin per AAP 400 IU/day vitamin D PO daily — Standard newborn supplementation (AAP newborn nutrition guidelines)

Non-pharmacologic actions:
- Parental kernicterus-prevention education at every visit — jaundice warning signs (face → torso → extremities cephalo-caudal progression; lethargy + poor feeding + arching) + when to seek evaluation
- G6PD-positive infant: long-term outpatient counseling on trigger-medication avoidance (sulfa drugs, nitrofurantoin, primaquine, methylene blue, fava beans)
- Lactation continued support if BF
- Hearing screen + audiology referral if abnormal
- Neurodevelopmental peds at 6 + 12 + 24 mo for at-risk infants
- Speech / language / OT / PT referrals if developmental delays
- Immunization catch-up per ACIP standard schedule
- Family adherence support + psychosocial barrier identification + social work if resource gaps

AVOID / contraindication checks:
- Ceftriaxone avoid under 28 days bilirubin displacement (AAP Puopolo 2018; FDA 2009) — CRITICAL in this engine because adding ceftriaxone in a hyperbilirubinemic neonate worsens free bilirubin from albumin displacement
- Sulfonamide avoid neonate bilirubin displacement (AAP Red Book 2024)
- Nitrofurantoin avoid G6PD positive infant hemolysis trigger (G6PD literature)
- Phototherapy avoid in conjugated hyperbilirubinemia rare bronze baby syndrome (Phototherapy literature)
- Phototherapy retinal protection eye shields required (Phototherapy literature)
- Phototherapy insensible water loss increase fluids 10 to 20pct (Phototherapy literature)
- Exchange transfusion citrate hypocalcemia monitor ionized calcium (Exchange procedure literature)
- Exchange transfusion irradiated CMV seronegative less than 7d blood required (Blood bank standards for neonatal exchange)
- IVIG rare hemolysis signal ABO setdown monitor CBC (Cochrane review caveat)
- Fluid bolus 10 to 20 mL per kg slower in neonate (AAP neonatal specific adaptation of SSC peds 2020)

Monitoring

Regimen monitoring:
- Serial TSB q6-12h on phototherapy until clearly declining; target decline ~ 0.5-1 mg/dL/h with intensive; ~ 0.2-0.5 mg/dL/h with standard
- Discontinue phototherapy when TSB ≥ 2 mg/dL below threshold for current hours-of-age
- Rebound TSB check at 12-24 h post-phototherapy discontinuation
- Daily weight + urine output + feeding tolerance
- CBC with retic at baseline + q24h if hemolysis (isoimmune or G6PD)
- Direct bilirubin fractionation if not initially measured + jaundice persists > 2 wk
- Post-exchange: ionized calcium + CBC + glucose + repeat TSB at 2 + 12 h
- G6PD-positive: trigger-medication audit (sulfa, nitrofurantoin, primaquine, methylene blue, fava beans) + parental counseling
- Hearing screen (AABR) before discharge for all infants requiring phototherapy (AAP 2022 + hearing screen routine)
- Neurodevelopmental screening at 6-12 mo if kernicterus risk (any ABE features, TSB approached exchange, prolonged severe hyperbilirubinemia)

Setting (outpatient) monitoring:
- Peds visit at 24-48 h post-discharge, 1 wk, 1 mo, 3 mo, 6 mo, 12 mo, then per standard schedule
- Bhutani-zone follow-up: high-intermediate or high → 24-48 h reassessment; low / low-intermediate → routine
- Rebound TSB check at 12-24 h post-phototherapy discontinuation if elevated risk
- Neurodevelopmental re-assessment at 6 + 12 + 24 mo for at-risk infants
- Hearing surveillance — repeat if any concern
- Immunization status audit at every visit until catch-up complete

Follow-up plan: Outpatient peds within 24-48 h of discharge for all phototherapy-treated infants + all high-risk (Bhutani high-intermediate/high percentile) + late preterm 35-36 wk + exclusive BF cohorts. Rebound TSB check at 12-24 h post-phototherapy discontinuation if elevated risk. G6PD-positive infant: long-term outpatient counseling on trigger-medication avoidance (sulfa drugs, nitrofurantoin, primaquine, methylene blue, fava beans). Lactation support continued + weight + feeding monitoring. Universal parental kernicterus-prevention education at every visit (jaundice warning signs, when to seek evaluation). Neurodevelopmental screening at 6-12 mo if kernicterus risk factors (any ABE features, TSB approached exchange, prolonged severe hyperbilirubinemia) — Bayley III or ASQ-3; hearing screen (AABR — sensorineural hearing loss is a kernicterus sequela). Audiology referral if hearing screen abnormal.
- Close-out criterion: Follow-up appointment confirmed + return precautions given + parental education delivered + neurodev plan if at-risk

Monitoring phase: Serial TSB q6-12h on phototherapy until clearly declining (target ~ 0.5-1 mg/dL per hour with intensive phototherapy; ~ 0.2-0.5 mg/dL per hour with standard phototherapy). Discontinue phototherapy when TSB ≥ 2 mg/dL below threshold for that hours-of-age. Rebound TSB at 12-24 h post-discontinuation. Daily weight + urine output + feeding tolerance. Phototherapy-specific monitoring: insensible water loss (increase fluids 10-20%), eye shields (retinal protection), loose stools, transient rash, conjugated component → STOP phototherapy (rare bronze-baby syndrome). Post-exchange: ionized calcium (citrate-induced hypocalcemia), CBC (thrombocytopenia), glucose, repeat TSB at 2 + 12 h post-exchange.

Disposition

Current setting: outpatient — Newborn nursery pre-discharge screening + outpatient peds follow-up post-discharge. Universal pre-discharge bilirubin screening with Bhutani-percentile risk stratification + follow-up timing. Home phototherapy in selected low-risk cases. Long-term G6PD-trigger counseling + neurodevelopmental screening for at-risk infants.

Disposition criteria:
- Sustained recovery — TSB resolved, growth at age-appropriate baseline, neurodevelopmental assessments within age-appropriate range, immunization catch-up complete, family demonstrating return-precaution knowledge, no symptomatic kernicterus sequelae

Escalation triggers (move to higher acuity):
- TSB rising despite home phototherapy OR not falling at expected rate → admission for intensive phototherapy + reassessment
- Worsening jaundice + lethargy + poor feeding + arching → emergent ED return; ABE rule-out + exchange-transfusion preparation
- Conjugated component emerging at > 2 wk (jaundice persists) → peds-GI/hepatology referral + biliary atresia rule-out by 4 wk (Kasai outcomes time-sensitive)
- Hearing loss confirmed on audiology → ENT + audiology + speech + early intervention
- Neurodevelopmental delay confirmed → developmental peds + PT/OT/speech
- G6PD-positive infant with hemolytic crisis after trigger exposure → ED + transfusion + ID consult

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] ABE neurologic features — lethargy + poor feeding + hypotonia OR hypertonia + opisthotonus + retrocollis + high-pitched cry — life-threatening pre-kernicterus phase; emergent exchange transfusion + ICU + neuro consult; reversible if caught early (Watchko & Tiribelli NEJM 2013; Kemper AAP 2022)
- [LIFE_THREATENING] TSB at or above AAP 2022 Figure 3 exchange-transfusion curve for gestational age + hours of age + risk factors — life-threatening; emergent exchange + intensive phototherapy + hematology + IVIG if isoimmune (Kemper AAP 2022 PMID 35927462)
- [SEVERE] Isoimmune hemolytic disease — DAT (Coombs) positive + maternal-infant ABO or Rh mismatch + rising bilirubin → IVIG 0.5-1 g/kg + intensive phototherapy + close monitoring; exchange if continued rise (Kemper AAP 2022; Cochrane IVIG reviews)

Citations

- Kemper KJ et al — AAP 2022 Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation — Pediatrics 2022 (PMID 35927462) — substantially revised 2004 thresholds; introduced escalation-of-care concept; universal G6PD testing in all infants requiring phototherapy; universal pre-discharge screening + Bhutani 1999 nomogram (PMID 9917432). Cross-references: Watchko & Tiribelli NEJM 2013 (kernicterus pathophysiology + ABE-kernicterus spectrum); Maisels CMAJ 2015 (operational review including home phototherapy); NICE NG98 (UK parallel guideline); Kimberlin Red Book 2021 (neonatal HSV cross-ref for conjugated hyperbilirubinemia with hepatitis). [PMID:35927462](https://pubmed.ncbi.nlm.nih.gov/35927462/)
- Cited evidence (PMID 35927519) [PMID:35927519](https://pubmed.ncbi.nlm.nih.gov/35927519/)
- Cited evidence (PMID 9917432) [PMID:9917432](https://pubmed.ncbi.nlm.nih.gov/9917432/)
- Cited evidence (PMID 30455342) [PMID:30455342](https://pubmed.ncbi.nlm.nih.gov/30455342/)
- Cited evidence (PMID 30455344) [PMID:30455344](https://pubmed.ncbi.nlm.nih.gov/30455344/)

Last reconciled with current guidelines: 2026-05-25.

References

Kemper KJ et al — AAP 2022 Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation — Pediatrics 2022 (PMID 35927462) — substantially revised 2004 thresholds; introduced escalation-of-care concept; universal G6PD testing in all infants requiring phototherapy; universal pre-discharge screening + Bhutani 1999 nomogram (PMID 9917432). Cross-references: Watchko & Tiribelli NEJM 2013 (kernicterus pathophysiology + ABE-kernicterus spectrum); Maisels CMAJ 2015 (operational review including home phototherapy); NICE NG98 (UK parallel guideline); Kimberlin Red Book 2021 (neonatal HSV cross-ref for conjugated hyperbilirubinemia with hepatitis). — PMID:35927462
Cited evidence (PMID 35927519) — PMID:35927519
Cited evidence (PMID 9917432) — PMID:9917432
Cited evidence (PMID 30455342) — PMID:30455342
Cited evidence (PMID 30455344) — PMID:30455344